Még nem toboroz
A Study of Lebrikizumab in Adults and Adolescents With Face and Neck Atopic Dermatitis
NCT07873801· 3. fázis· Almirall, S.A.· Forrás
Toboroz
A Study to Assess the Efficacy and Safety of GIA632 Across a Range of Doses in Participants With Moderate to Severe Cutaneous Lichen Planus
NCT07775924· 2. fázis· Novartis Pharmaceuticals· Forrás
Toboroz
A Phase 2b Study of the Effects of Camoteskimab in Adults with Moderate-to-Severe Atopic Dermatitis
2026-525673-39-00· 2. fázis· Apollo Therapeutics Limited· Forrás
Toboroz
A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis
NCT07711418· 3. fázis· Nektar Therapeutics· Forrás
Toboroz
An Extension Study to Assess Safety and Efficacy of Remibrutinib in Participants With Moderate to Severe HS
NCT07665437· 3. fázis· Novartis Pharmaceuticals· Forrás
Toboroz
A clinical trial to provide continued access to remibrutinib (LOU064) for people who are benefiting from it in a previous remibrutinib trial
2025-524078-40-00· 3. fázis· Novartis Pharma AG· Forrás
Toboroz
Long-term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants with Chronic Spontaneous Urticaria
2025-522878-36-00· 3. fázis· Celldex Therapeutics Inc.· Forrás
Toboroz
Continuation Study of Zasocitinib in Adults With Psoriatic Arthritis
NCT07286058· 3. fázis· Takeda· Forrás
Toboroz
A Phase IIb Dose-ranging Study to Assess the Efficacy and Safety of GIA632 in Participants With Non-segmental Vitiligo
NCT07431177· 2. fázis· Novartis Pharmaceuticals· Forrás
Még nem toboroz
A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with psoriatic arthritis (PsA)
2025-522471-28-00· 3. fázis· MoonLake Immunotherapeutics AG· Forrás
Toboroz
An Open-Label Extension Study of ORKA-001 in Participants With Plaque Psoriasis
NCT07449702· 2. fázis· Oruka Therapeutics, Inc.· Forrás
Fut, nem toboroz
A Study of Zasocitinib in Adults With Hidradenitis Suppurativa
NCT07244263· 2. fázis· Takeda· Forrás
Fut, nem toboroz
A Long Term Extension Study to Evaluate the Safety and Efficacy of Afimkibart (RO7790121) in Participants With Atopic Dermatitis
NCT07223697· 2. fázis· Hoffmann-La Roche· Forrás
Fut, nem toboroz
A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis
NCT07277660· 2. fázis· UCB Biopharma SRL· Forrás
Toboroz
A Study of LAD603 in Adults With Alopecia Areata
NCT07311564· 2. fázis· Almirall, S.A.· Forrás
Toboroz
A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis
NCT07250802· 3. fázis· Takeda· Forrás
Fut, nem toboroz
Dose Ranging Study of ORKA-001 in Patients With Moderate-to-Severe Plaque Psoriasis
NCT07290569· 2. fázis· Oruka Therapeutics, Inc.· Forrás
Fut, nem toboroz
A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis
NCT07217015· 2. fázis· Kymera Therapeutics, Inc.· Forrás
Fut, nem toboroz
A Study With CIT-013 in HS Patients
NCT06993233· 2. fázis· Citryll BV· Forrás
Toboroz
A first-in-human, dose finding study to evaluate the safety, tolerability and pharmacokinetics of EGL-003 in healthy volunteers followed by adults with autoimmune disease.
2025-521658-40-00· 1. fázis· Egle Therapeutics· Forrás
Fut, nem toboroz
A study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with moderate to severe hidradenitis suppurativa
2025-520564-17-00· 3. fázis· MoonLake Immunotherapeutics AG· Forrás
Toboroz
A Study to Evaluate the Long-term Safety and Effectiveness of APG777 in Subjects with Atopic Dermatitis
2024-519795-11-00· 2. fázis· Apogee Therapeutics Inc.· Forrás
Toboroz
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
NCT07116967· 3. fázis· Bristol-Myers Squibb· Forrás
Toboroz
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
NCT07037901· 2. fázis· Inmagene LLC· Forrás
Fut, nem toboroz
A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis
NCT06832618· 3. fázis· Incyte Corporation· Forrás
Fut, nem toboroz
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)
NCT06958211· 3. fázis· Incyte Corporation· Forrás
Toboroz
Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
NCT06947993· 2. fázis· Novartis Pharmaceuticals· Forrás
Fut, nem toboroz
A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis
NCT06934226· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis
NCT06863961· 2. fázis· Hoffmann-La Roche· Forrás
Fut, nem toboroz
A study to investigate the efficacy and safety of subcutaneous sonelokimab versus placebo in participants aged 18 years and over with active psoriatic arthritis who are naive to biologic DMARDs
2024-516213-20-00· 3. fázis· MoonLake Immunotherapeutics AG· Forrás
Fut, nem toboroz
A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa
NCT06840392· 3. fázis· Novartis Pharmaceuticals· Forrás
Fut, nem toboroz
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines
NCT06671483· 3. fázis· Takeda· Forrás
Toboroz
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
NCT06855498· 3. fázis· Incyte Corporation· Forrás
Fut, nem toboroz
A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis
NCT06878404· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
NCT06846541· 3. fázis· Alumis Inc· Forrás
Fut, nem toboroz
A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis
NCT06550076· 3. fázis· Takeda· Forrás
Fut, nem toboroz
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
NCT06461897· 3. fázis· AbbVie· Forrás
Fut, nem toboroz
A Phase 3 Study of Barzolvolimab in Participants With Chronic Spontaneous Urticaria (CSU)
NCT06455202· 3. fázis· Celldex Therapeutics· Forrás
Fut, nem toboroz
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
NCT06468228· 3. fázis· AbbVie· Forrás
Fut, nem toboroz
A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis
NCT06425549· 3. fázis· UCB Biopharma SRL· Forrás
Fut, nem toboroz
A Study Evaluating APG777 in Atopic Dermatitis
NCT06395948· 2. fázis· Apogee Therapeutics, Inc.· Forrás
Fut, nem toboroz
A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)
NCT06220604· 3. fázis· Janssen Research & Development, LLC· Forrás
Fut, nem toboroz
A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo
NCT06163326· 3. fázis· Pfizer· Forrás
Fut, nem toboroz
A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo
NCT06118411· 3. fázis· AbbVie· Forrás
Fut, nem toboroz
A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2)
NCT06113471· 3. fázis· Incyte Corporation· Forrás
Toboroz
Safety and immunologic response of SHIngrix VAccination in patients suffering from Psoriasis or Psoriatic arthritis
2024-512881-32-00· 4. fázis· Justus-Liebig-Universitaet Giessen· Forrás
Fut, nem toboroz
Phase 3b Study to Assess the Efficacy, Safety, and Tolerability of Remibrutinib in Comparison to Placebo, With Omalizumab as Active Control, in Adult CSU Patients, Followed by an Open-label 52-week Optional Extension.
NCT06042478· 3. fázis· Novartis Pharmaceuticals· Forrás
Fut, nem toboroz
A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis
NCT06136741· 2. fázis· Nektar Therapeutics· Forrás
Fut, nem toboroz
A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis
NCT06095115· 3. fázis· Janssen Research & Development, LLC· Forrás
Toboroz
A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata
NCT06012240· 3. fázis· AbbVie· Forrás
Showing 50 of 58.